AMPH — Amphastar Pharmaceuticals, Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1297184 ·
Last close
$19.98
Market Cap
$849.91M
52W High
$22.65
52W Low
$16.65
ADV30
442,315
Next earnings
2026-11-05
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 183,903,000 93,470,000 39,729,000 30,348,000 1,743,766,000 223,614,000 975,609,000
Mar 2026 171,171,000 70,322,000 13,630,000 6,420,000 1,648,162,000 170,939,000 874,771,000
Dec 2025 183,105,000 85,670,000 35,606,000 24,429,000 1,629,299,000 170,177,000 840,494,000
Sep 2025 191,840,000 98,646,000 25,320,000 17,350,000 1,666,222,000 216,265,000 889,476,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$168,878,000
Investing CF
$-97,546,000
Financing CF
$-83,129,000
CapEx
$-35,942,000
Dividends Paid
Buybacks
$-94,078,000
EPS Diluted TTM
$1.66
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$673,301,000
Inventory
$170,194,000
Receivables
$157,453,000
ST Investments
$121,012,000
EBIT TTM
$128,562,000
Pretax Income TTM
$102,814,000
Interest Exp TTM
$25,748,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$730,019,008
EBITDA
$194,514,000
Free Cash Flow
$230,095,872
Enterprise Value
$1,248,107,136
Total Cash
$290,123,008
Total Debt
$688,321,984
Shares Out
42,537,944
Trailing EPS
$1.69
Book Value
$18.06
ROE
10.3%
ROA
5.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 719,887,000 140,403,000 98,094,000 1,629,299,000 840,494,000 156,115,000
Dec 2024 731,967,000 205,419,000 159,519,000 1,577,470,000 845,172,000 213,386,000
Dec 2023 644,395,000 196,987,000 137,545,000 1,512,912,000 873,491,000 183,503,000
Dec 2022 498,987,000 107,497,000 91,386,000 741,987,000 213,329,000 89,181,000

TTM Snapshot

Revenues TTM
$604,097,000
NetIncome TTM
$135,073,000
OpCashFlow TTM
$0
Assets (Latest)
$1,577,470,000
Forward EPS
$3.05

Max Pain — expiry 2026-08-21

max pain strike: $20.00 · spot: $20.18 · call oi: 1,571 · put oi: 17
Expected Move to 2026-08-21: ±$2.50 (12.39%) — implied range $17.68$22.68 · ATM straddle on $20.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
IVEVF Inventiva S.A. $848.03M $3.59
ACRS Aclaris Therapeutics, Inc. $859.64M $5.84
MRVI MARAVAI LIFESCIENCES HOLDINGS, INC. $861.16M $5.78
PHAR Pharming Group N.V. $837.31M $11.83
COLL COLLEGIUM PHARMACEUTICAL, INC $833.55M $25.70

News headlines (Yahoo Finance, 1h cache)

AMPH Q2 Deep Dive: Portfolio Expansion and Pipeline Progress Drive Results
2026-08-11 08:13 · Yahoo
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
2026-08-06 23:30 · Yahoo
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates
2026-08-06 23:10 · Yahoo
Amphastar Pharmaceuticals Q2 Earnings Call Highlights
2026-08-06 23:03 · Yahoo
Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better-Than-Expected Sales In Q2 CY2026
2026-08-06 21:11 · Yahoo
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
2026-08-06 20:05 · Yahoo
1 Value Stock to Own for Decades and 2 Facing Challenges
2026-08-03 18:29 · Yahoo
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
2026-07-30 14:00 · Yahoo
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026
2026-07-29 10:00 · Yahoo
3 Reasons AMPH is Risky and 1 Stock to Buy Instead
2026-07-29 06:53 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.